NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services last week released preliminary gapfill rates for 2017 from its Medicare Administrative Contractors (MAC) for a number of molecular diagnostic tests.

CMS' proposed median payment would reduce pricing for CareDx's AlloMap by 74 percent to $732; Veracyte's Afirma GEC by 30 percent to $2,240; and Genomic Health's Oncotype DX Colon by 72 percent to $849. CMS has proposed to essentially maintain pricing for Myriad Genetics' Vectra DA at $587.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.